Adenomyosis Pregnancy Success Rate With Fertility-Sparing Treatment

Pregnancy success depends on the disease and treatment

A successful pregnancy with adenomyosis is possible, but there is no single adenomyosis pregnancy success rate that applies to everyone. A 2025 perspective review of uterus-sparing treatment in reproductive-aged women with adenomyosis reported pregnancy rates over 50% and live birth rates up to about 70% after excisional surgery for focal disease in selected patients. These are examples of reported outcomes, not a prediction of your individual chances.

Adenomyosis presents real trade-offs between controlling pain and bleeding, preserving the uterus, and planning a pregnancy. Uterus-sparing options include excisional surgery, procedures that treat tissue without cutting it out, and hormonal treatment used as part of a fertility plan. The choice depends heavily on whether disease is predominantly focal or diffuse, where it sits, and how much of the uterine wall is affected.

If you’d like a specialist’s second opinion on your imaging or a recommended treatment, our team can review it.

How adenomyosis and imaging shape fertility choices

Adenomyosis can affect fertility by changing uterine contractions, inflammation within the uterine muscle, and the lining’s receptivity to embryo implantation. Some people first learn they have adenomyosis during an infertility workup. Others have years of debilitating pain and heavy bleeding before pregnancy becomes a consideration.

Focal and diffuse findings

Diagnosis and classification are not perfectly standardized. One imaging report may describe “diffuse adenomyosis,” another may emphasize “junctional zone thickening,” and another may identify a “focal adenomyoma.”

A focal adenomyoma is a defined area that may be suitable for removal, while diffuse involvement is spread through the uterine muscle. These descriptions matter because they help determine which treatments are realistic and what pregnancy planning should look like afterward.

Location and junctional-zone involvement

The lesion’s location, its depth within the uterine wall, and the thickness and extent of junctional-zone involvement can influence fertility outcomes and treatment choices. The junctional zone is the inner portion of the uterine muscle next to the lining.

Ask your clinician to translate your imaging into a specific fertility plan. The discussion should go beyond naming the diagnosis to explain how its location and extent affect each option.

Excisional surgery for focal adenomyosis

An adenomyomectomy removes affected tissue and reconstructs the uterine wall while preserving the uterus. It is most straightforward when there is a defined focal adenomyoma and more complex when disease is widespread.

Pregnancy prospects with focal and diffuse disease

For selected patients with focal adenomyosis, the reported pregnancy rates over 50% and live birth rates up to about 70% are encouraging. Pregnancy and live birth are different outcomes, however, and reported percentages may use different definitions or denominators. Ask what each rate measures before applying it to your own situation.

Results are generally less successful with diffuse adenomyosis, where removing disease can compromise the strength of the uterus. A well-defined focal lesion, together with infertility or repeated implantation failure, may make excisional surgery worth considering as a direct way to change the anatomy and inflammatory environment.

Symptom relief and the limits of excision

All adenomyosis is at least partly diffuse, even when a focal adenomyoma is present. Diffuse disease cannot be fully excised, and symptoms may persist after adenomyomectomy if enough diffuse adenomyosis remains.

Removing a focal lesion therefore does not guarantee complete relief of pain or bleeding. Your surgeon should explain what can be removed, what will remain, and how that affects both symptom control and fertility planning.

Surgical trade-offs and uterine reconstruction

Adenomyomectomy is not a casual procedure. Surgeon skill, operative technique, and reconstruction quality matter enormously, and not every center has deep experience with this operation.

The procedure can involve blood loss, adhesions, and recovery time. Because it intentionally cuts into the uterine muscle, future pregnancy monitoring and delivery planning are essential parts of the decision, not optional additions.

Non-excisional uterus-sparing procedures

Not everyone is a good candidate for excisional surgery, and not everyone wants it. Non-excisional procedures aim to shrink, inactivate, or cut off the blood supply to adenomyosis tissue without removing it.

HIFU

High-intensity focused ultrasound, or HIFU, uses focused ultrasound energy to heat and destroy targeted tissue. Treatment is guided by imaging, often MRI or ultrasound.

In selected patients, reported pregnancy rates are around 40–53%, with live birth rates around 35–74% across studies and techniques. These wide ranges reflect differences in patient selection, adenomyosis subtype, treatment technique, and definitions of success. They should not be read as a single expected outcome for everyone considering HIFU.

RFA

Radiofrequency ablation, or RFA, uses a probe to deliver energy directly into adenomyosis tissue, heating and destroying it. Ultrasound guidance is often used, and transvaginal and transcervical approaches exist.

RFA can be less invasive than excision. For some people, it may reduce symptoms with a shorter recovery, but its fertility outcomes should be discussed separately from those of HIFU or UAE.

UAE

Uterine artery embolization, or UAE, is an interventional radiology procedure that blocks blood supply to uterine tissue to shrink lesions and reduce symptoms. It is more established for fibroids than for adenomyosis, and fertility planning requires a particularly explicit discussion.

If pregnancy is a priority, ask about ovarian reserve, placental risks, and local experience with UAE for fertility preservation. Preserving the uterus and choosing the best procedure for a future pregnancy are not necessarily the same decision.

How the approaches compare for fertility

Some pooled analyses summarized in the 2025 review found no statistically significant differences in pregnancy, live birth, or miscarriage rates between excisional and non-excisional approaches. This does not make the procedures interchangeable for an individual or establish that one category always performs better.

Your lesion type, location, and junctional-zone changes often drive the choice more than the procedure’s name. Broad comparisons also combine people with different disease patterns and treatments, which can obscure differences that matter to your own fertility plan.

Hormone therapy as part of a fertility plan

Treatment is generally best viewed as a process, not a single event. A plan may combine a procedure with temporary hormonal suppression before or afterward, coordinated with attempts at conception or IVF.

Why GnRH agonists may be recommended

GnRH agonists are commonly considered as an adjunct to uterus-sparing treatment. The aim is to suppress estrogen temporarily, calm inflammation, and reduce adenomyosis activity.

Adjunct hormonal therapy appears to improve outcomes in some settings, particularly when coordinated with a fertility plan. Your doctor should explain how suppression fits into the timing of natural conception attempts or IVF rather than treating it as an isolated prescription.

Duration, side effects, and add-back therapy

GnRH agonists can cause menopause-like side effects, including hot flashes, mood changes, disrupted sleep, and low libido. Sometimes add-back hormone therapy is used to make treatment more tolerable.

If years of hormonal trial-and-error have worn you down, ask for the shortest effective course and a plan that protects your mental health. The choice of medication, duration, side-effect management, and tolerability all belong in the treatment discussion.

Pregnancy risks and delivery planning after treatment

Preserving the uterus does not guarantee a usual-risk pregnancy afterward. Conservative surgery and some non-excisional treatments can change the uterine wall and the environment in which the placenta attaches.

Placenta accreta spectrum

Placenta accreta spectrum involves abnormal placental attachment and can cause severe bleeding at delivery. The risk varies, but it warrants direct counseling and appropriate monitoring during pregnancy.

Ask how your adenomyosis and proposed treatment could affect placental attachment. This discussion should be part of fertility planning before a procedure is chosen.

Uterine rupture after conservative surgery

Uterine rupture rates up to about 6% have been reported in some conservative-surgery series, particularly with diffuse disease and deeper uterine-wall reconstruction. That figure is not a universal risk after every fertility-sparing procedure.

The relevant discussion is how your disease pattern, the amount of muscle affected, and the planned reconstruction influence your individual risk. Your surgeon should also explain how those findings will affect pregnancy management.

Pregnancy monitoring and delivery

Planning may include close imaging surveillance during pregnancy, delivery at a hospital equipped for complex obstetrics, and, in many cases, planned cesarean delivery rather than labor. Monitoring should be individualized to the procedure and uterine repair.

Your doctor should be able to explain why a particular delivery plan is recommended. The procedure performed and the details of reconstruction matter when deciding both the mode and timing of delivery.

Choosing a treatment and building a fertility plan

Match imaging and symptoms to the options

A useful plan brings together your imaging, pain and bleeding, age, fertility history, and any previous IVF or implantation failures. The most influential imaging features are often focal versus diffuse involvement, lesion location and depth, and junctional-zone thickness or extent.

The experience of the team performing the specific procedure matters as well. Ask about outcomes in people with disease and fertility histories similar to yours, rather than relying only on a center’s overall pregnancy rate.

The plan should also include a fertility timeline: natural conception attempts versus IVF, whether hormonal suppression should come first, and how long to wait after a procedure before trying to conceive. These decisions are part of treatment, not details to leave until afterward.

Questions to take to your doctor

• Based on my imaging, is this mostly focal or diffuse adenomyosis? Where is it located, how deep does it extend, and how thick is the junctional zone?
• Am I a candidate for adenomyomectomy?
• Would you consider HIFU, RFA, or UAE for someone trying to preserve fertility like me? What makes me a good or poor candidate?
• What pregnancy and live birth rates do you typically see in patients like me, with the same subtype, age, and IVF history, rather than just overall averages?
• Would you recommend GnRH agonist therapy or another hormonal approach around treatment? For how long, and how will side effects be managed?
• If I conceive, what is the plan for pregnancy monitoring and delivery? Do you recommend a planned cesarean, and at what gestational age?

Why published outcomes may differ from yours

Much of the published information on fertility-sparing adenomyosis treatment comes from small or retrospective studies. Techniques vary between surgeons and centers, and disease subtype, severity, and pregnancy outcomes are not reported consistently.

There are also few robust randomized trials comparing procedures with one another, medical treatment, or trying to conceive without a procedure. A published success rate is therefore most useful when your clinician can explain how closely the people studied, their disease patterns, and their treatment match your situation.